What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to disclose changes in executive compensation for Wayne S. DeVeydt, Executive Vice President, Chief Financial Officer and Chief Accounting Officer of WellPoint, Inc. This includes updates to his salary, bonus targets, stock options, and restricted stock units.

What performance metrics will determine Mr. DeVeydt's 2007 bonus?

Mr. DeVeydt's 2007 annual bonus will be determined by performance measures including adjusted diluted Earnings Per Share (40%), Operating Gain (20%), Specialty Performance (15%), Medical Membership Growth (15%), Member Health Index (5%), and Member Trust (5%). Crucially, a threshold level of adjusted diluted Earnings Per Share must be achieved for any bonus to be paid.

When will Mr. DeVeydt's stock options and restricted stock units vest?

The promotional stock options will vest in six equal semi-annual installments over three years, beginning January 2, 2008. The promotional restricted stock units will vest in three equal annual installments over three years, beginning July 2, 2008, provided that the adjusted diluted Earnings Per Share for 2007 meets a specified threshold.

Are there any conditions attached to the payment of the annual incentive bonus?

Yes, a significant condition is that if the threshold adjusted diluted Earnings Per Share is not achieved, no 2007 Annual Incentive Bonus will be paid. Additionally, while executives can earn up to 300% of their target bonus based on performance, the maximum cash award is capped at 200% of the target, with any earned amounts exceeding this paid in restricted stock units.

ELV 8-K: Leadership Changes

Summary

This Form 8-K filing by WellPoint, Inc. (now Elevance Health) on June 11, 2007, primarily details executive compensation adjustments for Wayne S. DeVeydt, EVP, CFO, and Chief Accounting Officer. The filing outlines his new salary, annual bonus target, stock option grant, and restricted stock unit award, effective in mid-June 2007. These changes reflect his role and responsibilities within the company and are tied to specific performance metrics and vesting schedules, providing insight into the company's incentives for key financial leadership. For investors, this report signals continued investment in and commitment to its financial leadership team. The performance metrics tied to Mr. DeVeydt's bonus (such as adjusted diluted Earnings Per Share and Operating Gain) indicate key areas of focus for the company's financial performance. The stock option and restricted stock unit grants represent a long-term incentive designed to align executive interests with shareholder value creation, subject to specific performance thresholds and vesting periods.

Key Highlights

1Effective June 11, 2007, Wayne S. DeVeydt's annual salary was set at $600,000.
2Mr. DeVeydt's 2007 Annual Bonus Target Percentage was established at 75% of his annual salary.
3A promotional stock option grant of 13,333 options was approved for Mr. DeVeydt.
4A promotional restricted stock unit award of 1,667 units was approved for Mr. DeVeydt.
5The 2007 annual incentive bonus is contingent on achieving specified performance measures, including adjusted diluted Earnings Per Share (40%) and Operating Gain (20%).
6A threshold achievement of adjusted diluted Earnings Per Share is required for any annual incentive bonus to be paid.
7Stock options vest over three years, and restricted stock units vest over three years, contingent on 2007 performance thresholds.

Elevance Health, Inc. 8-K Report, Executive Changes (Jun 11, 2007)

Summary

Key Highlights

Frequently Asked Questions